Approximately 15% of ER-positive HER2-negative BC patients are likely to have recurrence at the 5-year timeline in the absence of adjuvant chemotherapy[6] and 85% of patients are likely to be exposed to chemotherapeutic toxicity with minimal clinical benefit. Here, ERBB2 is linked to breast cancer.